Markus Ralser, and his team in the Molecular Biology of Metabolism Laboratory,
have created a fast, cheap and reliable platform technology that can measure the levels of protein in blood plasma. Until now, similar technologies have been held back due to slowness and unreliability.
Their work means that a human sample can be tested, at low cost, in less than five minutes. Measuring the levels of protein in blood plasma can be used to predict how a patient will respond to certain treatments – their molecular signature.
This data can then be coupled with a machine-learning workflow to predict population heterogeneity (diversity/variation). A collaboration with the MRC Epidemiology unit aims to predict the prevalence of metabolic diseases, such as diabetes.
The research was made possible through the support of two internal Crick translational grants, and support from Barbara Domayne-Hayman, the Crick’s Entrepreneur in Residence, who provided the team with expertise, advice on commercialisation, and relevant commercial connections.